ELISA Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5)

TRAP; TrATPase; Tartrate Resistant Acid Phosphatase; Type 5 acid phosphatase


This assay has high sensitivity and excellent specificity for detection of Acid Phosphatase 5, Tartrate Resistant (ACP5).
No significant cross-reactivity or interference between Acid Phosphatase 5, Tartrate Resistant (ACP5) and analogues was observed.


Matrices listed below were spiked with certain level of recombinant Acid Phosphatase 5, Tartrate Resistant (ACP5) and the recovery rates were calculated by comparing the measured value to the expected amount of Acid Phosphatase 5, Tartrate Resistant (ACP5) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 97-104 101
EDTA plasma(n=5) 89-96 92
heparin plasma(n=5) 78-95 83


Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Acid Phosphatase 5, Tartrate Resistant (ACP5) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Acid Phosphatase 5, Tartrate Resistant (ACP5) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%


The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Acid Phosphatase 5, Tartrate Resistant (ACP5) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 91-98% 80-92% 78-104% 89-103%
EDTA plasma(n=5) 99-105% 90-99% 88-102% 89-101%
heparin plasma(n=5) 85-101% 81-101% 84-101% 97-105%


The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.



Magazine Citations
Archives of Oral Biology Oxytocin promotes bone formation during the alveolar healing process in old acyclic female rats ScienceDirect: S0003996912001021
Life Sciences Exendin-4 Increases Bone Mineral Density in Type 2 Diabetic OLETF Rats Potentially Through the Down-Regulation of SOST/Sclerostin in Osteocytes PubMed: 23357248
International Journal of Cardiology Valvular osteoclasts in calcification and aortic valve stenosis severity. Pubmed: 23452891
Evidence-Based Complementary and Alternative Medicine Antiosteoporosis Activity of New Oriental Medicine Preparation (Kyungokgo Mixed with Water Extract of Hovenia dulcis) on the Ovariectomized Mice Pubmed:25737735
Advances in Medical Sciences The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats PubMed: 26569440
Bone The effects of strength training and raloxifene on bone health in aging ovariectomized rats Pubmed:26812611
Journal of Clinical Medicine Research In Vitro and In Vivo Effects of Gracilaria verrucosa Extracts on Osteoclast Differentiation. pubmed:28335442
Biomedicine & Pharmacotherapy Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats S0753332216322752
Clinical Trials in Degenerative Diseases Correlating oxidative stress-related factors with bone metabolic markers in older adult male patients exhibiting degenerative osteoporosis in the high-altitude hypoxic area of China: study protocol for a non-randomized controlled trial issn:2542-3975
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPA902Hu01 Recombinant Acid Phosphatase 5, Tartrate Resistant (ACP5) Positive Control; Immunogen; SDS-PAGE; WB.
PAA902Hu01 Polyclonal Antibody to Acid Phosphatase 5, Tartrate Resistant (ACP5) WB; IHC; ICC; IP.
MAA902Hu22 Monoclonal Antibody to Acid Phosphatase 5, Tartrate Resistant (ACP5) WB; IHC; ICC; IP.
SEA902Hu ELISA Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5) Enzyme-linked immunosorbent assay for Antigen Detection.